High Content Screening

This is the latest episode of the free DDW podcast, “Finding the right cancer drug with high-content screening”. It covers an article by the same name written for Volume 23, Issue 1 – Winter 2021/22 of DDW. In the article, Lassi Paavolainen, Principal Investigator at the Institute for Molecular Medicine Finland (FIMM), Vilja Pietiäinen, Adjunct […]

The cell painting approach evokes new ideas and strategies for high-content screening (HCS) practitioners to identify new drugs and to study mechanisms of action by leveraging machine learning to measure subtle phenotypic changes at the cellular level. Dr. Alexander Schreiner, HCS Applications Leader, PerkinElmer and Dr. Martin Daffertshofer, High Content Screening Software Product Manager, PerkinElmer […]

PerkinElmer has launched the first cell painting kit as part of its new portfolio of PhenoVue cellular imaging reagents. This new range of reagents leverages PerkinElmer’s expertise in cellular imaging and high-content screening and works alongside its microplates, automation, software and high-content screening instruments. With this entire screening workflow, researchers can better understand disease and […]

PerkinElmer will acquire Horizon Discovery for approximately $383 million (£296 million). The transaction is expected to close in the first quarter of 2021 subject to conditions. The investment will allow PerkinElmer to expand its portfolio of leading, automated life sciences discovery and applied genomics solutions to include gene editing and gene modulation tools. The acquisition […]

By Ibis Sanchez-Serrano and Rathnam Chaguturu Mitigation of COVID-19 pandemic requires a combination of effective epidemiological policies and the discovery/development of powerful drugs against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) that causes this disease. This article examines the major initiatives being explored at the public policy level to contain the spread of COVID-19 […]

THE COVID-19 RACE how mouse models will help researchers cross the finish line By Dr Megan MacBride The emergence of SARS-CoV-2 virus and the disease it causes, COVID-19, have fuelled significant shifts in preclinical research across the globe. Amid the worldwide health emergency created by high infection rates, rapid transmission spread and relatively high mortality […]

By Dr Karin Bottcher High content screening (HCS) has played a significant role in infectious disease research and drug discovery to date and can be a strong tool in the age of COVID-19 and beyond. With a focus on viral diseases, this article will describe how HCS has been used by laboratories around the world […]

The COVID-19 antiviral race: we’re all in this together By Uduak Grace Thomas In response to the COVID-19 pandemic, international scientists from academia and industry have pooled their expertise and resources to identify candidate compounds that inhibit the activity of the SARS-CoV-2 main protease, in order to develop a clinically effective antiviral. The aptly named […]

The CELL CULTURE innovations increasing drug discovery success By Helen Stewart-Miller and Abby George Volume 21 Issue 3 – Summer 2020 ‘Fail early, fail fast’ has been a mantra in the pharmaceutical industry for several years and directly impacts the overall strategy of many drug discovery and development programmes. Yet, despite the drive to fail […]

The Personalized Medicine Coalition The Personalized Medicine Coalition (PMC), representing a broad spectrum of academic, industrial, patient, provider, and payer communities, seeks to advance the understanding and adoption of personalized medicine concepts and products for the benefit of patients. As part of its mission, the PMC publishes The Case for Personalized Medicine. Since the first […]